New developments in antiplatelet therapy

European Heart Journal, Supplement

Volumn 10, Issue D, 2008, Pages

  Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

AZD6140; Cangrelor; P2Y12 antagonists; Platelet aggregation; Prasugrel

Indexed keywords

CLOPIDOGREL; TICAGRELOR;

ANTICOAGULATION; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; HUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

EID: 58249133717     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sun008     Document Type: Conference Paper

References (13)

1. 12 receptor. Curr Pharm Des 2006;12:1255-1259.
2. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamics effects of the platelet ADP-receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002;13:407-413.
3. 12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 2008;19:125-133.
4. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-66.e16.
5. 12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373.
6. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM the TRITONTIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2015-2021.
7. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
8. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-1860.
9. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF for the DISPERSE2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral ADP-receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndromes: primary results of the DISPERSE2 trial. J Am Coll Cardiol 2007;50:1844-1851.
10. Storey RF, Husted S, Harrington RA Heptinstall S, Wilcox RG, Gurbel PA, Grande P, Sanders N, Peters G, Emanuelsson H, Cannon CP. AZD6140 yields greater inhibition of platelet aggregation than clopidogrel in patients with acute coronary syndromes without previous clopidogrel treatment. J Am Coll Cardiol 2006;47(Suppl. A):204A. Abstract 821-823
11. 12 antagonist AZD6140 compared with the thienopyridine clopidogrel in both a rat and a dog model of combined thrombosis and haemostasis. Presented at: The XXIst International Society on Thrombosis and Haemostasis Congress. Geneva, Switzerland; 6-12 July 2007.
12. Storey RF, Oldroyd KG, Wilcox RG. Open multicenter study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001;85:401-407.
13. 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006;151:689.e1-689.e10.